News Hub | News Direct

Sevita Named Among “America’s Best Employers for Diversity” by Forbes

Sevita

Sevita, a leading national provider of home and community-based health care and support services, has been named by Forbes as one of “America’s Best Employers for Diversity” in 2023. The recognition was presented to organizations that have demonstrated progress in reducing racial and socioeconomic inequities in their workplaces and communities. This year’s recognition marks the third consecutive year Sevita has received this accolade. “We are honored to be recognized as a Best Place to Work for Diversity,” said Natasha Hudspeth, Sevita’s Vice President, Talent and Chief Diversity Officer. “This award is a testament to our commitment to our core values of integrity, respect, inclusion, and growth, which are at the heart of all that we do.” Hudspeth continued: “At Sevita, we believe diversity is a strength, and this continued recognition reaffirms our dedication to creating an environment where individuals are valued, respected, and provided equal opportunities to thrive at work and in the communities we call home. We understand that embracing diversity both enriches our culture and drives innovation, creativity, and success. This recognition further fuels our determination to continuously improve and cultivate an inclusive workplace where every team member can bring their whole self, share their unique perspective, and together, achieve remarkable growth.” According to Forbes and Statista Inc., the world-leading statistics portal and industry ranking provider, this year’s list was compiled using survey data “from approximately 45,000 U.S. employees working for companies with a minimum of 1,000 employees.” The evaluation was based on criteria including employee opinions on current workplace diversity as well as evaluation of other, comparator employers’ diversity efforts and best practices. This award comes off the heels of Sevita’s launch of its Employee Resource Groups (ERGs) and the expansion of its Inclusion Council, both of which are working to build a collaborative environment for Sevita employees. Sevita’s ERGs were established earlier this year with the goal of bringing employees together to connect around shared identities, experiences, and interests ranging from LGBTQIA+ team members and allies; DEIB; Veterans, Military Service Members, and Families; employees who have disabilities; and more. At the same time, Sevita’s Inclusion Council has since expanded to include seven state-based Inclusion Committees. “Sevita and the Inclusion Council have done an amazing amount of great work over the past year to strengthen our work community and show that employees should feel seen, heard, and valued,” said Inclusion Council co-chair Jennifer Allen, program director for NeuroRestorative, a member of the Sevita family. “The creation of local level inclusion committees and various employee resource groups are just some of the projects that are fostering opportunities for employees from across the country to connect, teach, learn, and grow both personally and professionally.” In addition to being recognized for diversity three years in a row, Sevita was also previously recognized by Forbes as one of “America’s Best Employers by State” in 2019 (then operating as The MENTOR Network). Learn more at forbes.com/lists/best-employers-diversity. _______ Sevita is hiring! Our employees are at the heart of what we do. They bring their care, compassion, and expertise to work each day to make our mission possible. We know that when we work from a shared mission and set of values, we can change lives for the better. Learn more about who we are and what it’s like to work at Sevita or start your application at jobs.sevitahealth.com Sevita is a leading provider of community-based specialized health care, inspired by our core values of respect, integrity, inclusion and growth. We provide people with quality services and individualized supports that lead to growth and independence, despite the physical, intellectual, or behavioral challenges they face. We’ve made this our mission for more than 50 years. Today our team members continue to innovate and enhance care for the 50,000+ individuals we serve. sevitahealth.com Contact Details Melissa Patricio media@sevitahealth.com Company Website https://sevitahealth.com/

July 17, 2023 10:00 AM Eastern Daylight Time

News Release

POSaBIT Systems leading the way for retailers and dispensaries with point of sale technology

POSaBIT Systems Corporation

POSaBIT Systems Corp CEO Ryan Hamlin joined Steve Darling from Proactive to share exciting news about the company's solutions for dispensary payments and payment processing in the cannabis industry. POSaBIT provides a range of solutions for both point-of-sale and payment needs for dispensaries and cannabis retailers. Hamlin highlighted that POSaBIT is well-positioned for growth, even in the event of potential changes to legislation by the Federal Government in the United States. The company has been steadily increasing its market share and driving product innovation in a fragmented market. In fact, POSaBIT's market share in Washington State has risen from 5% to 40% within a few years, demonstrating their strong presence and success. Furthermore, Hamlin shared the company's ambitious goals for the future. POSaBIT aims to reach $2 billion in processing volume over the next 18 months, highlighting their potential for significant growth in transactional value. Additionally, the company aims to onboard 2,000 merchants onto the POSaBIT point-of-sale system within the same timeframe, further expanding their customer base and market reach. Hamlin also discussed the company's aspirations to uplist to the Nasdaq and the TSX, indicating their focus on achieving greater visibility and market presence. This potential uplisting would further enhance POSaBIT's reputation and attract more investors to support their continued growth. With its comprehensive payment and POS solutions tailored for the cannabis industry, POSaBIT is well-positioned to capitalize on the expanding market and evolving regulatory landscape. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

July 14, 2023 03:47 PM Eastern Daylight Time

Video

Kush Kriminals: A Beacon of Transparency in the NFT Universe

Kush Kriminals

Kush Kriminals, the trailblazing entertainment franchise, is taking a stand in the NFT space with its commitment to full transparency. This pledge is a testament to the brand's dedication to fostering trust and providing tangible value in the digital collectibles arena. Transparency: A Core Value In the dynamic world of NFTs, Kush Kriminals recognize the crucial role of transparency. The brand is committed to an open dialogue with its community, providing clear and consistent updates about the creation process, the artists involved, and the inherent value of the NFTs. All team bios and concerns can be found on the Kush Kriminals website, reflecting the brand's policy to be as open as possible. “We understand why other creators choose to hide behind their PFP,” said Jimmy Holman, Co-Founder of Kush Kriminals.” But given the nature of this project, we felt it imperative to be as open and accessible as possible to our community from day one.” The Masterminds Behind Kush Kriminals Led by a team of talented creators, including the much-acclaimed comic writer Sam Humphries, recognized for his work with Marvel and DC Comics. Adding an element of intrigue to our universe is the contribution of a highly regarded 'mystery' artist, who chooses to let their art speak for them within the Kush Kriminals realm. The combined expertise and talent of these artists are evident in the high-quality Kush Kriminals NFTs. Their combined creativity offers a captivating blend of engaging narratives and compelling visuals, setting a high bar within the NFT space. Ensuring Value for Investors Kush Kriminals is not just about creating digital art; it's about providing tangible value for its community. The brand's commitment to transparency ensures that potential investors can trust in the value of the NFTs, making Kush Kriminals a reliable choice in the digital collectibles space. Join the Kush Kriminals Universe Kush Kriminals extends an open invitation to enthusiasts to join a vibrant, thriving community. This community is not just about buying and selling; it's a space for interaction, discussion, and collective growth. With a fully doxxed team, Kush Kriminals ensures complete transparency, building trust and confidence among its community members. The Kush Kriminals NFTs are a testament to the highest standards of excellence in the digital collectibles space. With the ease of purchase facilitated by Magic Eden, acquiring these high-quality NFTs is a breeze. But it's not just about owning digital art; it's about becoming part of an immersive universe that's set to expand through a captivating comic series. As a holder of Kush Kriminals NFTs, you'll have the opportunity to participate in future developments, adding an exciting dimension to your investment. Moreover, Kush Kriminals is proud of its real-world utility. With partnerships with Cookies and other dispensaries across the nation, the brand is bridging the gap between the digital and physical worlds. To learn more and become part of this transformative project, visit www.kushkriminals.com or contact the team at info@kushkriminals.com. About Kush Kriminals Kush Kriminals is a pioneering entertainment franchise dedicated to providing top-tier digital art experiences that cater to the evolving needs of the digital art and cryptocurrency communities. With a team of industry experts, including renowned comic writer Sam Humphries, Kush Kriminals is committed to innovation and transparency. The brand's clear roadmap includes expanding the Kush Kriminals universe through a compelling comic series, offering followers the opportunity to participate in future developments. With its high-quality NFTs, immersive experience, and real-world utility, Kush Kriminals is shaping the future of digital collectibles and establishing itself as a trusted leader in the NFT space. Contact Details For press inquiries, please contact: Celeste Morrison, Public Relations Director, Groundswole LLC celeste@groundswole.com Company Website https://kushkriminals.com/

July 14, 2023 07:00 AM Eastern Daylight Time

Image

News Release

BioVie to present neurodegenerative research at Alzheimer’s Associate’s International Conference

BioVie Inc

BioVie Chief Medical Officer Dr. Joe Palumbo joins Natalie Stoberman from the Proactive newsroom to share how the company plans to present its research on neurodegenerative diseases at the Alzheimer’s Associate’s International Conference (AAIC) to be held in Amsterdam July 16-20. Dr. Palumbo says BioVie will showcase its NE3107 molecule and discuss how patients with clinical dementia treated with NE3107 for three months were able to see significant reductions in the level of DNA methylation and how the correlation of those reductions led to improvements in various cognitive measures. Dr. Palumbo explains that neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including Alzheimer’s Disease, Parkinson’s Disease, dementia and ALS. He says NE3107 is an oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation. NE3107’s potential to inhibit neuroinflammation and insulin resistance forms the basis for the company’s work testing the molecule in AD and PD patients. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

July 13, 2023 04:26 PM Eastern Daylight Time

Video

News Release

Nevis Brands CEO reveals success story and future growth plans

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to provide an update on the company's operations, which they say is very different from most listed cannabis companies. Nevis Brands is a provider of cannabis brands in the United States and offers expansion opportunities worldwide. The company currently supplies products in Washington, Oregon, California, Ohio, Arizona, and Colorado through partnerships and licensees. The company has announced they have been approved for listing on the Canadian Securities Exchange under the ticker “NEVI.” Kueber explained one of their flagship products is Major, which has established itself as one of the best-selling cannabis beverages globally. Major was launched in March 2019 by the creators of Happy Apple, quickly gaining recognition as the top-selling THC beverage in Washington State. What sets Major apart is its utilization of SōRSE, a proprietary water-soluble emulsion technology. This technology enhances the consumption experience of cannabis, making it easier, safer, and more enjoyable. With an average onset time of 8-15 minutes, consumers no longer have to wait for a significant cannabis experience. Nevis Brands continues to innovate in the cannabis industry, offering high-quality products and leveraging cutting-edge technology to provide consumers with exceptional cannabis experiences. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

July 13, 2023 03:46 PM Eastern Daylight Time

Video

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

NanoViricides

Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides Inc (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy. Savin gives an overview of what the company does, as well as its current operations and its financial situation. He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 13, 2023 08:31 AM Eastern Daylight Time

Video

Cellular Goods provides update on King Tide Carbon integration

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor speaks to Thomas Warner from Proactive about how the acquisition of biosynthetic algae & seaweed carbon sequestration as-a-service company King Tide Carbon (KTC) has been proceeding since it completed back in May. Taylor says that the acquisition of King Tide Carbon has allowed Cellular Goods to expand its vision of sustainability and capitalise on the increasing demand for carbon removal solutions driven by the Paris Climate Agreement. He goes on to emphasise the importance of bio-synthetics as an emerging technology for carbon removal and highlighted the expertise of the King Tide team in accelerating the company's direction. With the acquisition, Cellular Goods aims to be at the forefront of scalable and high-quality carbon removal solutions, contributing to the fight against climate change while delivering value to shareholders. He also addresses how long he is likely to stay in the interim CEO role, saying that his main priority is to deliver growth and development for the business and that he "remains committed for the next twelve months and beyond." He also commits to providing more frequent updates to shareholders. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 12, 2023 06:16 AM Eastern Daylight Time

Video

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Client Valley

Las Vegas, NV - Mechelle Evans, the founder of GLO by ME SKIN, is pleased to announce her new company dedicated to revolutionizing the skincare industry. With a focus on providing excellent services and education, Mechelle is transforming the way individuals care for their skin. Mechelle, an esteemed Aesthetician, believes that healthy and glowing skin is a birthright for everyone. Recognizing the skin as the body's largest organ, she emphasizes the importance of proper skincare. Through a comprehensive range of services, Mechelle helps her clients achieve their skin goals, whether it's combating acne, reducing wrinkles, or maintaining overall skin health. However, Mechelle's mission extends beyond offering services; she is dedicated to educating individuals about the significance of skincare. She emphasizes the harmful effects of UV rays and environmental pollutants on the skin, which can lead to premature aging and other skin conditions. By instilling the importance of regular facials, proper cleansing, and the use of high-quality products, Mechelle empowers her clients to protect and enhance their skin's health. Mechelle's journey into skincare began in the early 1990s when she worked as a television extra. Witnessing the damage caused by heavy makeup and sun exposure, she became determined to maintain her own skin's health. Her introduction to Dr. Obagi, a renowned skincare expert, solidified her belief in the transformative power of skincare, prompting her to further educate herself on the subject. Motivated by her passion for helping others achieve clear and healthy skin, Mechelle made the life-changing decision to become a full-time aesthetician. Despite leaving behind a six-figure salary, she was driven by a greater purpose. Mechelle aimed to make a lasting impact on people's lives and be remembered for making a real difference. As an advanced licensed professional specializing in melanated skin, Mechelle offers a wide range of services, personalized skincare recommendations, and advanced treatments like chemical peels, microneedling, and lasers. Her goal is to provide effective solutions tailored to diverse skin tones, challenging prevailing mindsets that discourage treatment for such skin types. Driven by her dedication to delivering results, Mechelle embarked on creating her own skincare line. Her flagship product, a 1% retinol, stands out for its ability to address multiple skin types and deliver exceptional results. Infused with powerful antioxidants, essential amino acids, minerals, and botanical moisturizers, this retinol promotes healthy cell regeneration and collagen production, resulting in reduced visible signs of aging, diminished pores, and blemishes. Through GLO by ME SKIN, Mechelle Evans is redefining skincare by combining the power of education, quality treatments, and effective products. With her advanced knowledge, personalized approach, and commitment to inclusivity, she has become a trusted advisor and advocate for skin health. In a world where healthy skin is highly valued, Mechelle's vision of empowering individuals to embrace their natural beauty and achieve a healthy complexion is becoming a reality. Her expertise, passion, and transformative results have earned her a reputation as a leading force in the skincare industry. As Mechelle continues to leave her mark on the field, her dedication and expertise are changing lives. Through GLO by ME SKIN, she is making a genuine difference, leaving a lasting legacy as someone who revolutionized skincare and helped individuals achieve radiant, healthy skin. About Mechelle Evans: Mechelle Evans is the founder of GLO by ME SKIN, a skincare brand dedicated to providing innovative and effective skincare solutions. With a passion for skincare and a commitment to education, Mechelle offers personalized services and products to help individuals achieve healthy and radiant skin. Her expertise and transformative results have earned her recognition as a trusted advisor in the skincare industry. Contact Details GLO by ME SKIN Crissy Henry office@9figuremedia.com Company Website http://www.globyme.com/

July 11, 2023 05:24 PM Eastern Daylight Time

Image

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company’s licensee and co-developer in India. NanoViricides has been building out a novel nanomedicine platform for many years, and this platform now includes a pipeline of multiple preclinical antiviral drugs. The Company is developing antiviral medications that are built on the company’s patented nanoviricide technology. Nanomedicine has a lot of promise, but there are almost no nanomedicines available on the market to treat viral infections. Because of prior acquired expertise, NanoViricides’ first-in-class COVID drug, NV-CoV-2, took just about one year to complete IND-enabling studies, from the discovery stage in January 2020. As a small company with a novel mechanism implemented using out-of-the-box technologies, it took the Company much longer time to actually start clinical trials. Now that it has this regulatory experience, additional drug developments should not take such a long lag time. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, President and Executive Chairman of NanoViricides. NanoViricides’ Treatment Of Coronaviruses The company’s first drug candidate is NV-CoV-2, a broad-spectrum, anti-coronavirus treatment. Other companies have developed treatments for COVID-19, These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD). However, there are limitations or drawbacks to each of these treatments. As a broad-spectrum anti-coronavirus drug, NV-CoV-2 has been shown to work against a variety of unrelated coronaviruses. This suggests that different strains or mutations are unlikely to escape the drug. Several common coronavirus strains include hCoV-229E, hCoV-OC43, hCoV-HKU1, and hCoV-NL63, which recur seasonally. Of these, NL63 and OC43 present with pneumonia similar to the delta COVID variant in susceptible patients, leading to fatalities at rates that are comparable to seasonal influenza. Now, SARS-CoV-2 with its variants is added to this list as a commonly occurring coronavirus. A Nanomedicine Platform For Other Viruses The trials for NV-CoV-2 are part of the company’s development of a novel platform technology employing nanoviricides. The NV-CoV-2 drug contains NV-387, a first-in-class chemical nanomedicine, and its unique mechanism of action (MoA) doesn’t rely on the patient’s immune system to destroy the virus. The Company says that NV-387 mimics an attachment receptor family to which over 90% of known viruses bind, and NanoViricides hopes that NV-387 will likely be a clinically effective drug against at least a few of these viruses. The Company has said that it has begun R&D work to expand the indications of NV-387 to other viruses. By bringing NV-CoV-2 to human trial, NanoViricides has demonstrated the platform’s capability to deliver a clinically relevant antiviral. After the Phase 1 studies are completed, the safety and tolerability data will be applicable to any other viruses that the Company targets using NV-CoV-2, assuming it can demonstrate pre-clinical success. Then NV-387 can directly enter Phase 2 as an antiviral against such additional viruses — which would likely mean significant cost and time savings for the additional indications, and substantial improvement in the return on investment (ROI) for the Company with commensurate benefits to the investors. The Company is not a “one-trick pony” either. It already has NV-HHV-1, a drug to treat shingles rashes, that has completed pre-clinical studies. The company believes its platform could provide treatments for a host of viruses, including other herpesviruses (cold sores, genital ulcers, and many other serious diseases), as well as influenza and HIV. This would position NanoViricides at the intersection of multiple growing treatment markets. The herpes treatment market was worth $1.5 billion in 2022 and is predicted to grow at a compound annual growth rate (CAGR) of 9.2% over the next seven years. The influenza market is expected to reach $1.2 billion by 2026, while the HIV market is predicted to reach $36 billion by 2027. For now, however, the company is keeping laser-focus on the development of NV-CoV-2 for treating COVID-19 and long COVID. Its current trial will test the drug’s safety and efficacy, and the data will be used to prepare for phase 2 trials. “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations,” said Diwan. “Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Learn more about how NanoViricides is tackling different viruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 11, 2023 09:25 AM Eastern Daylight Time

Healthcare

Sevita Named Among “America’s Best Employers for Diversity” by Forbes

POSaBIT Systems leading the way for retailers and dispensaries with point of sale technology

Kush Kriminals: A Beacon of Transparency in the NFT Universe

BioVie to present neurodegenerative research at Alzheimer’s Associate’s International Conference

Nevis Brands CEO reveals success story and future growth plans

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

Cellular Goods provides update on King Tide Carbon integration

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?